University of Vermont

The University of Vermont Cancer Center

trials_gyno.html

Gynecological Cancer Clinical Trials

The University of Vermont Cancer Center has trials specifically focused on gynecological cancer research.

Status: Active - Recruiting
Study Title: GOG-3005/M13-694 - A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Purpose: The purpose of this study is to compare the combination of carboplatin, paclitaxel and veliparib to carboplatin, paclitaxel, and placebo (a substance that looks like the real medication but has no active ingredients) followed by continued therapy with either veliparib or placebo to determine if it slows the progression of Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
ClinicalTrials.gov Identifier: NCT02470585
Contact: Jennifer Holmes (802) 847-3453
Information: https://clinicaltrials.gov/ct2/show/study/NCT02470585?term=m13-694&rank=1&show_locs=Y#locn
Institution Number: M15-584
Protocol Research Type: Industry Sponsored
Status: Active - Recruiting
Study Title: GOG-0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC #91485) versus Pacllitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, stage IVB, or Recurrent Endometrial Cancer
Purpose: The purpose of this study is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating advanced or recurrent endometrial (uterine) cancer and to find out what side effects are caused by treatment with these drugs.
ClinicalTrials.gov Identifier: NCT02065687
Contact: Jennifer Holmes (802) 847-3453
Information: https://clinicaltrials.gov/ct2/show/NCT02065687?term=gog-0286b&rank=1
Institution Number: M14-461
Protocol Research Type: Cooperative Group (GOG)

Last modified February 19 2016 09:49 AM